期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 86, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2020.106697
关键词
Gambogic acid; LPS-induced mastitis; NF-kappa B; MAPK; Apoptosis; Blood-milk barrier
资金
- National Key Research and Development Plan [2016YFD0500906]
- special fund for the China Agriculture Research System (Beef/Yak cattle) [CARS-37]
- National Natural Science Foundation of China [31972758]
- Research Fund for National Distinguished Scholars in Agriculture Research and Technical Innovative Team
Mastitis is one of the most common diseases among dairy cows. There is still much debate worldwide as to whether antibiotic therapy should be given to dairy cows, or if natural products should be taken as a substitute for antibacterial therapy. As the antibiotic treatment leads to the bacterial resistance and drug residue in milk, introducing natural products for mastitis is becoming a trend. This study investigates the mechanisms of the protective effects of the natural product gambogic acid (GA) in lipopolysaccharide (LPS)-induced mastitis. For in vitro treatments, it was found that GA reduced IL-6, TNF-alpha, and IL-1 beta levels by inhibiting the phosphorylation of proteins in the nuclear factor kappa B (NF-kappa B) and the mitogen-activated protein kinase (MAPK) pathway. GA also maintained a stable membrane mitochondrial potential and inhibited the overproduction of reactive oxygen species, which protected the cells from apoptosis. On the other hand, in vivo treatments with GA were found to reduce pathological symptoms markedly, and protected the blood-milk barrier from damage induced by LPS. The results demonstrate that GA plays a vital role in suppressing inflammation, alleviating the apoptosis effect, and protecting the blood-milk barrier in mastitis induced by LPS. Thus, these results suggest that the natural product GA plays a potential role in mastitis treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据